Lionheart III Corp Warrant (LIONW) Peer Comparison
$0.11
$0.00
(3.45%)
As on 07-Mar-2023 16:00EDT
Market cap
$-- Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Edit
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
-- | 5,749 | 746 | 451 | 373 |
Revenue ($ Mln) |
-- | 440 | -- | 330 | 58 |
Net Profit ($ Mln) |
-3.66 | -1,435.01 | -134.20 | 100.20 | -50.70 |
Net Margin (%) |
-- | -325.91 | -- | 30.33 | -88.09 |
RoE (%) |
-- | -- | -40.17 | 30.44 | -54.90 |
Price to Earnings |
-- | -- | -- | 4.72 | -- |
Price-To-Book |
-- | -- | -- | 1.32 | 2.54 |
Income Statement ($ Mln)
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 544.48 | 32.22 | 228.69 | 27.44 |
|
Cost of Revenue
|
0.00 | 305.62 | 0.30 | 182.25 | 22.48 |
|
Gross Profit
|
-- | 238.86 | 31.92 | 46.44 | 4.96 |
|
Operating Expenses
|
3.84 | 5.21 | 162.14 | 56.85 | 62.72 |
|
Operating Profit (EBIT)
|
-3.84 | -5.21 | -129.92 | -10.42 | -57.76 |
|
Other Income
|
0.00 | -- | 0.86 | -18.08 | 0.76 |
|
Profit before Tax
|
-3.11 | -32.50 | -131.76 | -10.42 | -107.09 |
|
Provision for Tax
|
0.12 | 15.76 | -- | -6.70 | 0.07 |
|
Profit after Tax (Net Income)
|
-3.66 | -32.50 | -131.76 | -57.92 | -107.09 |
|
Minority Interest
|
0.00 | -- | -- | 19.55 | -- |
|
Consolidated Profit
|
0.00 | 47.31 | -131.76 | -57.92 | 10.20 |
Liabilities ($ Mln)
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
120.07 | 280.79 | 286.12 | 331.96 | 110.42 |
|
Minority Interest
|
0.00 | -- | -- | 19.55 | -- |
|
Non-Current Liabilities
|
4.38 | 61.37 | 76.52 | 158.50 | 145.64 |
|
Current Liabilities
|
3.19 | 4.21 | 63.02 | 324.88 | 46.66 |
|
Total Liabilities
|
128.02 | 346.37 | 425.65 | 2,698.57 | 302.72 |
Assets ($ Mln)
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
126.98 | 345.03 | 156.48 | 824.54 | 34.64 |
|
Current Assets
|
0.65 | 1.33 | 269.18 | 1,951.91 | 268.07 |
|
Total Assets
|
128.02 | 346.37 | 425.65 | 2,698.57 | 302.72 |
|
Total Debt*
|
0.00 | 818.81 | 23.64 | 158.74 | 19.51 |
|
Net Current Assets
|
-2.54 | 436.27 | 206.16 | -- | 0.84 |
Cashflow ($ Mln)
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.41 | -1.87 | -75.62 | -295.39 | -56.40 |
|
Cash Flow from Investing Activities
|
-- | -423.84 | 92.22 | 251.38 | -33.59 |
|
Cash from Financing Activities
|
128.07 | 347.84 | 1.08 | -12.21 | 282.89 |
|
Net Cash Inflow / Outflow
|
-- | -- | 17.68 | -56.22 | 1.13 |
Ratios
Profitability Ratios
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | -5.10 | -34.71 | -11.07 | -694.65 |
|
ROE (%)
|
-- | -15.68 | -39.23 | -15.92 | -8,256.82 |
|
ROA (%)
|
-5.56 | -11.36 | -27.90 | -2.09 | -63.86 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -5.97 | -398.26 | -27.50 | -379.73 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | 8.03 | -0.50 | -0.73 | 0.45 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-- | -166.25 | -138.01 | 39.95 | -391.09 |
|
EPS Growth (%)
|
-- | -1.66 | -1.24 | 0.40 | -1.00 |
|
Book Value Growth (%)
|
374,633,600.00 | -- | -- | -- | -- |
Valuation Ratios
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-21.02 | -106.90 | -19.34 | -3.15 | -3.56 |
|
Price / Book Value
|
0.06 | 12.37 | 8.91 | 0.55 | 3.46 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-16.97 | 70.38 | -17.58 | -50.19 | -1.74 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 2.92 | 0.08 | 0.48 | 0.18 |
|
Short term debt to equity ratio
|
0.00 | 0.37 | 0.07 | 0.01 | 0.07 |
|
Current Ratio
|
0.20 | 0.32 | 4.27 | 6.01 | 5.75 |
|
Quick Ratio
|
0.20 | -- | 4.26 | 7.13 | 5.26 |
|
Interest Coverage
|
-3.24 | 0.62 | -49.89 | -0.12 | -38.08 |
Operating Efficiency Ratios
| Lionheart III Corp Warrant (LIONW) | Core Scientific Inc (CORZ) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | Velocitycquisition Corp. Class A (VELO) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | 0.31 | 1.28 | 470.64 | 47.57 |
|
Asset Turnover
|
0.00 | 1.90 | 0.07 | 0.08 | 0.16 |
|
Receivable days
|
-- | 0.94 | 3.29 | 1,585.02 | 115.26 |
|
Inventory Days
|
-- | -- | 1,029.23 | -1,955.46 | 241.98 |
|
Payable days
|
-- | 1.98 | 11,865.18 | 659.05 | 90.24 |
|
Cash Conversion Cycle
|
-- | -- | -10,832.66 | -1,029.48 | 267.00 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
